Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Trial Profile

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions
  • Acronyms EASE LID 2
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
    • 24 Aug 2017 According to an Adamas Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
    • 08 Jun 2017 Interim (n=223) results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top